We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




High Blood Glucose Tied to Cardiovascular Risk in Diabetes

By LabMedica International staff writers
Posted on 14 Aug 2020
Print article
By measuring glycated hemoglobin (HbA1c), clinicians are able to get an overall picture of what the average blood sugar levels have been over a period of weeks/months (Photo courtesy of Diabetes.co.uk).
By measuring glycated hemoglobin (HbA1c), clinicians are able to get an overall picture of what the average blood sugar levels have been over a period of weeks/months (Photo courtesy of Diabetes.co.uk).
Glycated hemoglobin (HbA1c) is a measure of an overall picture of what the average blood sugar levels have been over a period of weeks/months. If the blood sugar levels have been high over recent weeks, the hemoglobinA1c test will be higher.

Blood sugar is commonly considered too high if it is higher than 130 mg/dL before a meal or higher than 180 mg/dL two hours after the first bite of a meal. However, most of the signs and symptoms of high blood sugar do not appear until the blood sugar level is higher than 250 mg/dL.

Clinical Scientists at the Miguel Hernandez University (San Juan de Alicante, Spain) conducted a study with an aim to analyze the relationship between HbA1c levels, blood sugar and mayor adverse cardiovascular events (MACE) risk in diabetes patients over 70 years of age. In total 5,016 subjects were included with a mean age of 75.1 years (46.7% men). Primary endpoint was the incidence of MACE: all-cause mortality and/or hospital admission due to coronary heart disease or stroke.

The scientists reported that during an average follow-up of 49 months (4.1 years), 807 (16.1%) MACE were recorded. The incidence of MACE was 20.6 per 1,000-person-years. Variables significantly associated to the incidence of MACE were male gender (HR: 1.61), heart failure (HR: 2.26), antiplatelet therapy (HR: 1.39), oral antidiabetic treatment (HR: 0.74), antithrombotic treatment (HR: 1.79), while age, creatinine, HbA1c and peripheral arterial disease were time-depend associated variables.

The authors concluded that their results highlights the importance of HbA1c level in the incidence of cardiovascular events in older diabetic patients. The study was originally published online on June 27, 2020 in the journal Primary Care Diabetes.

Related Links:

Miguel Hernandez University

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.